Pricing Log in Create free account
Saturday 17 October 2026 Export DXCM’s income statement to Excel — free account

DexCom, Inc.

DXCM Healthcare Medical Devices

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue grew 13.1%, EPS grew 41.3%, free cash flow fell 11.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

86.06 1.65 −1.88%
Market cap
$33.1B
P/E
33.2×
Fwd P/E
29.8×
Dividend yield
—
F-score
8/9
Altman Z
6.43
Beneish M
−2.70
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

DexCom, Inc. (DXCM) EV/EBITDA

Alert me on EV/EBITDA

As of 16 October 2026, DexCom, Inc. (DXCM) trades at a EV/EBITDA of 23.5×. Over the past ten years it has ranged from 0.0× (December 2019) to 860× (November 2018); the current reading is higher than 46% of that period. That is above the Medical Devices industry median of 11.5× and above the Healthcare sector median of 9.2×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 22.3× (39.38%)
FY2024 36.7× (40.01%)
FY2023 61.2× (24.18%)
FY2022 80.8× (41.99%)
FY2021 139× 50.72%
FY2020 92.4× (9.37%)
FY2019 102× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 18.4× (0.06%)
Mar 2026 18.4× (17.36%)
Dec 2025 22.3× (8.98%)
Sep 2025 24.5× (32.18%)
42 more quarters

Against its own ten years

Low 0.0× High 860×
Ten-year median 30.4×
Current reading's percentile 46

EV/EBITDA against peers

Company EV/EBITDA
SNN Smith & Nephew SNATS, Inc. compare 6.0×
PHG Koninklijke Philips N.V. compare 8.8×
ZBH Zimmer Biomet Holdings, Inc. compare 11.0×
GEHC GE HealthCare Technologies Inc. compare 12.3×
BSX Boston Scientific Corporation compare 13.9×
STE STERIS plc compare 14.2×
DXCM DexCom, Inc. 23.5×
EW Edwards Lifesciences Corporation compare 29.0×
PEN Penumbra, Inc. compare 58.6×
Medical Devices industry median 11.5×
Healthcare sector median 9.2×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on DXCM